iPSC derived NK cells - Pipeline Insight, 2024

This “IPSCs derived NK cells - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 30+ pipeline drugs in IPSCs derived NK cells pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

IPSCs derived NK cells Understanding

IPSCs derived NK cells: Overview

The discovery of human pluripotent stem cells (PSCs) at the turn of the century opened the door to a new generation of regenerative medicine research. Among PSCs, the donors available for induced pluripotent stem cells (i PSCs) are greatest, providing a potentially universal cell source for all types of cell therapies including cancer immunotherapies using natural killer (NK cells). Unlike primary NK cells, those prepared from i PSCs can be prepared with a homogeneous quality and are easily modified to exert a desired response to tumor cells. iPSC-derived NK (iNK) cells produce inflammatory cytokines and exerted strong cytotoxicity against an array of hematologic and solid tumors. There already exist several protocols to genetically modify and differentiate iPSCs into NK cells, and each has its own advantages with regardstoimmunotherapies.

IPSCs derived NK cells - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the IPSCs derived NK cells pipeline landscape is provided which includes the disease overview and IPSCs derived NK cells treatment guidelines. The assessment part of the report embraces, in depth IPSCs derived NK cells commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, IPSCs derived NK cells collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence IPSCs derived NK cells R&D. The therapies under development are focused on novel approaches to treat/improve IPSCs derived NK cells.

IPSCs derived NK cells Emerging Drugs Chapters

This segment of the IPSCs derived NK cells report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

IPSCs derived NK cells Emerging Drugs

EG-HZ: Eye GeneA varicella-zoster virus vaccine (EG HZ) is a non-live, recombinant subunit vaccine being developed by EyeGene to prevent i PSCs derived NK cells caused by the varicella-zoster virus (VZV). The vaccine combines a recombinant antigen, glycoprotein E (VZVgE), and CIA05, an adjuvant system which is a non-toxic LOS-derived substance with optimal immunologic activity. A Phase I clinical trial evaluating the EG-HZ vaccine hasbeencompleted.

CRV1O1: Curevo Vaccine CRV-101 is a next-generation shingles vaccine candidate designed to maximize the CMI protection by combining the gE protein antigen with our proprietary adjuvant. Curevo's CRV-101 is an investigational adjuvanted subunit vaccine for the indication of the prevention of IPSCs derived NK cells in older adults. The adjuvanted subunit vaccine strategy contrasts with traditional approaches using live killed or attenuated viruses. Sub-unit vaccines do not contain virus components and cannot cause infection. The adjuvant component was specifically engineered to produce an optional immune response while using a smaller amount of adjuvant with a targeted structure-function approach. CRV101 is being developed in Phase I stage of development to treat IPSCs derived NKcells.

IPSCs derived NK cells: Therapeutic Assessment

This segment of the report provides insights about the different IPSCs derived NK cells drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in IPSCs derived NK cells

There are approx. 15+ key companies which are developing the therapies for IPSCs derived NK cells. The companies which have their IPSCs derived NK cells drug candidates in the most advanced stage, i.e. Phase I include, Changchun BCHT Biotechnology.

Phases

This report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

IPSCs derived NK cells pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

IPSCs derived NK cells: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses IPSCs derived NK cells therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging IPSCs derived NK cells drugs.

IPSCs derived NK cells Report Insights

• IPSCs derived NK cells Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

IPSCs derived NK cells Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing IPSCs derived NK cells drugs?
• How many IPSCs derived NK cells drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of IPSCs derived NK cells?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the IPSCs derived NK cells therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for IPSCs derived NK cells and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 1-3 business days.